GlassScriptPhysician profile
Jogendra Singh
NPI 1174998843
$13,001.36
in general payments reported to CMS, 2019-2025
28 companies · $4,385 in 2025
The $4,385 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,205 · 2022: $1,543 · 2023: $2,679 · 2024: $3,189 · 2025: $4,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $32.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,220.71 |
| Education | $32.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,636.87 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $1,559.60 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,211.99 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,142.37 | 2021-2025 | Caplyta |
| Abbvie INC. | $996.72 | 2021-2025 | |
| Alkermes, INC. | $986.34 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $969.23 | 2021-2025 | Invega Sustenna, Spravato |
| E.R. Squibb & Sons, L.L.C. | $850.39 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $475.69 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $372.65 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $363.07 | 2021-2025 | Trintellix |
| Corium, LLC | $344.80 | 2021-2025 | Azstarys, Azstarys |
| Bausch Health US, LLC | $288.88 | 2022-2025 | Aplenzin |
| Almatica Pharma LLC | $286.82 | 2021-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $281.51 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $248.81 | 2022-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $246.10 | 2022-2025 | Qelbree, Qelbree |
| Idorsia Pharmaceuticals US INC | $180.46 | 2023-2024 | Quviviq |
| Tris Pharma INC | $178.32 | 2023-2024 | Dyanavel Xr |
| Indivior INC. | $171.75 | 2021-2024 | Perseris |
| Sage Therapeutics, LLC | $68.14 | 2023-2025 | Zurzuvae |
| Noven Therapeutics, LLC | $38.32 | 2024-2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $29.38 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $17.18 | 2022 | |
| Neos Therapeutics, LP | $15.57 | 2025 | Adzenys Xr-Odt |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.16 | 2025 | Abilify Asimtufii, Abilify Maintena |
| Brainsway USA INC | $13.43 | 2023 | |
| Eisai INC. | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jogendra Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.